QURATIS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,283 KRW | +3.30% |
|
-3.90% | -41.28% |
| 2023 | Quratis Inc. announced that it has received KRW 7.99999791 billion in funding from LINFRA Corp | CI |
| 2023 | Quratis Inc. announced that it expects to receive KRW 7.99999791 billion in funding | CI |
| 1 day | +3.30% | ||
| 1 week | -3.90% | ||
| Current month | -3.90% | ||
| 1 month | -14.47% | ||
| 3 months | -38.47% | ||
| 6 months | -49.78% | ||
| Current year | -41.28% |
1 week
1 127.00
1 341.00
1 month
1 127.001 545.00
Current year
1 127.002 335.00
1 year
1 127.006 690.00
3 years
1 127.006 690.00
5 years
1 127.006 690.00
10 years
1 127.006 690.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kwan-Gu Cho
CEO | Chief Executive Officer | - | - |
Quratis Inc is a Korea-based company primarily engaged in the manufacture and sale of biopharmaceuticals. The Company is engaged in the manufacture and sale of vaccine, peptide nucleic acid complex. The Company is also engaged in the provision of Cell Penetrating Peptide (CPP) platform services. In addition, the Company is engaged in the development and research of vaccines, such as tuberculosis vaccines for adults and adolescents, and COVID-19 vaccines.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -41.28% | 39.25M | |
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B |
- Stock Market
- Equities
- A348080 Stock
